CNBC on MSN14d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
which allows commercially insured patients without coverage for Zepbound to buy a month's supply for around $650. Under that ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version between February and March 2025.
Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Crain's New York26d
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Patients seeking to buy Zepbound from the company can connect with a telehealth provider for a diagnosis and prescription, skipping an in-person trip to the doctor or pharmacy. Companies including ...
Hosted on MSN5d
Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?
Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...